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Relaxin decreases renal interstitial fibrosis and slows progres- ies, we have shown that the ACE inhibitor enalapril
sion of renal disease. reduced interstitial fibrosis, decreased the production of
Background. Relaxin, a hormone of the insulin-growth fac- transforming growth factor-b (TGF-b), and increasedtor family, promotes collagen remodeling. In rodent models
gelatinase activity in the bromoethylamine (BEA) modelof pulmonary and dermal fibrosis, relaxin reduced interstitial
of renal fibrosis [1, 2]. In this model, an initial papillaryfibrosis. To study relaxin’s effect in renal disease, we used the
experimental bromoethylamine (BEA) model that leads to necrosis is followed by extensive interstitial fibrosis and
severe renal interstitial fibrosis, a decrease in glomerular filtra- renal insufficiency [3].
tion rate, and albuminuria at one month. Relaxin, a hormone of the insulin growth factor family,Methods. Rats were injected with BEA one week prior to
has a broad range of biologic activities, including induc-implantation of an osmotic pump delivering relaxin (2 mg/hour)
tion of collagen remodeling mediated by effects on colla-or vehicle continuously for 28 days.
Results. BEA caused a significant decrease in creatinine gen and collagenase synthesis [4, 5]. The purpose of
clearance, which was partially prevented by relaxin. In the this study was to determine the effect of a continuous
relaxin-treated BEA rats, serum creatinine was normal, and infusion of relaxin on the progression of BEA-inducedalbumin excretion was slightly decreased. By morphometric
renal papillary necrosis and interstitial fibrosis.measurement, relaxin administration was associated with a sig-
nificant decrease in interstitial fibrosis at the corticomedullary
junction. This was accompanied by a decrease in the number
METHODSof ED-1 positive cells (an index of macrophage infiltration)
and in the intensity of immunohistochemical staining for trans- Experimental design
forming growth factor-b. This antifibrotic effect of relaxin did
Male Sprague-Dawley rats (Harlan), weighing 250 gnot appear to be mediated by systemic hemodynamic changes
since the mean arterial pressure was not significantly different at the beginning of the study, were housed individually
among the groups. on a standard 12:12 light-dark cycle with free access to
Conclusions. Relaxin may have a useful application in de- standard rat chow (PMI #5012; PMI Feeds, Inc., St.
creasing interstitial fibrosis and thereby slowing the progression
Louis, MO, USA) and drinking fluid. The animals wereof renal disease.
conditioned to handling and tail-cuff blood pressure
measurement (IITC Life Science, Woodland Hills, CA,
USA) for three weeks prior to the experimental period.Efforts to prevent the progression of renal diseases
All animals had a stable blood pressure at that time. Thehave relied largely on dietary protein restriction and
experiments were conducted in accord with the Nationalthe use of antihypertensive drugs, especially angiotensin-
Institutes of Health guidelines for the care and use ofconverting enzyme (ACE) inhibitors. In previous stud-
laboratory animals and were approved by the institu-
tional review board.
1 See Editorial by Becker and Hewitson, p. 1184. Groups of conditioned rats were injected intraperito-
neally with BEA (200 mg/kg body weight) or vehicleKey words: growth factors, transforming growth factor-b, papillary
necrosis, bromoethylamine. (0.9% sterile saline). Renal balance studies were done
at one-week post-BEA to insure that all animals hadReceived for publication July 27, 2000
papillary necrosis, as evidenced by increased urinary out-and in revised form October 3, 2000
Accepted for publication October 6, 2000 put and decreased urine specific gravity. Animals were
then randomly assigned to treatment groups. OsmoticÓ 2001 by the International Society of Nephrology
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minipumps (Alzet model 2 ML4; Alza Corp., Palo Alto, olis, IN, USA). The secondary antibody was conjugated
to alkaline phosphatase and visualized with Fast RedCA, USA) filled with either relaxin [Recombinant hu-
man relaxin, ConXne; 2 mg/h; Connetics Corp., Palo Naphthol (Sigma, St. Louis, MO, USA). Positively
stained cells were counted in 20 adjacent 340 fields atAlto, CA, USA (Rlx)] or vehicle (20 mmol/L sodium
acetate, pH 5.0) were implanted subcutaneously between the corticomedullary junction and in 50 glomeruli.
The primary TGF-b antibody was a rabbit polyclonalthe scapulae. Blood pressures were measured twice
weekly for the next 26 days. At that time, a second obtained from Promega Corp. (Madison, WI, USA). As
previously discussed in this article, an alkaline phospha-minipump containing 14C inulin was placed in the perito-
neal cavity. Animals were allowed to recover for 24 tase-Fast Red Naphthol detection system was used.
Staining intensity was quantitated on digitized imageshours, and two 24-hour urine collections with midpoint
blood collections were obtained for measuring glomeru- using Sigma Scan (SPSS, Chicago, IL, USA). In each
section, intensity measurements were made of the tu-lar filtration rate (GFR) in conscious animals [6, 7]. At
day 28, another 24-hour urine collection was obtained bules bordering the fibrosis, normal tubules, and the
background. A ratio of staining intensities minus back-for creatinine clearance. Following this, animals were
anesthetized with sodium pentobarbital (50 mg/kg), and ground was obtained for each section. This ratio was
used for comparisons among groups.blood samples were taken from the descending aorta
and renal vein. The kidneys were perfused retrogradely
Gelatinase assaywith cold saline. One kidney was removed for collagen-
ase studies, and the other was perfused in situ with 50 mL Gelatinase activity was quantitated by a fluorescence
assay with gelatin FITC as the substrate as previouslyof HistoChoice (Amresco Inc., Solon, OH, USA) and
processed for routine histology. described [2, 8]. Tissue extracts were adjusted to 0.5
mg/mL protein for this assay. Fluorescence was mea-
Biochemical studies sured at excitation 491 and emission 519. The amount
of gelatin degraded was determined by comparing theUrine and plasma creatinine and inulin were measured
by standard methods. Urine albumin was measured by samples to a standard prepared by maximally digesting 1
to 20 mg/mL of FITC gelatin with clostridial collagenase.radial immunodiffusion on plates obtained from The
Binding Site (Birmingham, UK). Gelatinase activity as measured by this assay yields the
net available gelatinolytic activity that is free of tissue
Relaxin enzyme-linked immunosorbent assay (ELISA) inhibitors of metalloproteinase (TIMP) inhibition.
Serum relaxin levels were quantitated by a sandwich
Morphometric analysisimmunoassay [5]. Briefly, wells of a microtiter plate
(Maxisorp Immunomodules; Nunc, Naperville, IL, USA) Interstitial fibrosis was evaluated at the corticomedul-
lary junction on Masson’s trichrome-stained coronal sec-were coated overnight with affinity-purified goat anti-
human recombinant relaxin polyclonal antibody. After tions. We defined this area as that portion of the cortex
inferior to the juxtamedullary glomeruli and consistingan overnight incubation, wells were washed, and 100 mL
of diluted affinity-purified rabbit anti-human recombi- of the outer stripe and the superior portion of the inner
stripe of the outer medulla. Care was taken not to includenant relaxin polyclonal antibody conjugated to peroxi-
dase were added to each well. Following an appropriate the inner medulla in these measurements. Contiguous
fields encompassing the total C-M junction were photo-incubation period and color development with tetra-
methylbenzidene, the reaction was stopped by acidifica- graphed at 34 and were digitized. The area of fibrosis,
including the interstitial cell infiltrate and atrophic tu-tion. Absorbencies at 450/630 nm were measured, and
concentrations of individual sera were determined by bules, was measured. Papillary necrosis was measured
on periodic acid-Schiff–stained digitized sections. Theseentering data into a four-parameter logistic curve-fitting
program. A standard curve of recombinant human re- images included the tip and approximately three fourths
of the papilla. This area was chosen because only inlaxin ranging from approximately 12 to 750 pg/mL was
run on each assay plate. The assay has been validated the animals receiving BEA alone did the lesion extend
beyond this point. Measurements were made using Sigmafor use with rat serum (that is, recovery, linearity of
dilution, lower limit of detection, intra-assay, and in- Scan (SPSS) and were expressed as a percentage of the
total area.terassay precision) and has a sensitivity of approximately
15 pg/mL. Sera were run at no less than a 1:20 dilution;
Statisticstherefore, the sensitivity in serum is 300 pg/mL.
Except as indicated, data were expressed as mean 6
Immunohistochemistry SE. Statistical analyses [analysis of variance (ANOVA),
regression analysis, and t test] were performed whereMacrophages were identified with a mouse mono-
clonal antibody to ED-1 (Harlan Bioproducts, Indianap- appropriate using SigmaStat (SPSS).
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Table 1. Urine specific gravity and output
Specific Specific Urine volume
gravity gravity mL/hr
before after 28 days after 28 days
Treatment relaxin of relaxin of relaxin
None 1.026 6 0.005 1.032 6 0.003 1.11 6 0.14
N 5 8
Relaxin 1.031 6 0.005 1.037 6 0.008 0.87 6 0.26
N 5 6
BEA 1.017 6 0.001a 1.017 6 0.002a 2.18 6 0.23a
N 5 11
BEA 1 1.018 6 0.001a 1.019 6 0.002a 1.86 6 0.12a
relaxin
N 5 15
aSignificantly different from control at P # 0.005
Fig. 1. Comparison of serum creatinine at five weeks. Bromoethyl-
amine (BEA) 1 relaxin treatment: BEA one week before, then relaxin
treatment for four weeks. *P , 0.05 compared with BEA alone; #P ,
0.05 compared with the control.
Table 2. Mean arterial pressures (mm Hg) at representative
time points
1 week 1 week
Treatment after BEA after relaxin Final
Control 116 6 2 114 6 6 117 6 1
Relaxin 119 6 3 116 6 9 123 6 3
BEA 109 6 6 98 6 8 114 6 4
BEA 1 relaxin 118 6 4 113 6 4 110 6 7
RESULTS
Effect of treatment with relaxin on
functional parameters
One month after BEA injection, there was complete
necrosis of the papilla with interstitial fibrosis, a mononu- Fig. 2. Comparison of glomerular filtration rate, shown here as creati-
nine clearance. BEA 1 relaxin treatment: BEA one week before, thenclear cell infiltrate, and tubular atrophy. As seen in Table
relaxin treatment for four weeks. *P , 0.05 compared with BEA alone;1, animals receiving BEA, with or without relaxin treat-
#P , 0.05 compared with the control.
ment, had a significant concentrating defect, indicating
that papillary necrosis had taken place. Relaxin alone did
not affect the urine-specific gravity or induce a diuresis at
any time during the experimental period. Serum relaxin P 5 0.004). The results of the inulin clearances were
levels in the control and untreated BEA animals were similar (controls 0.65 6 0.13 vs. BEA 0.38 6 0.02 mL/
below the detectable limit of the assay. The levels in min/100 g body weight). Relaxin reversed this trend and
animals receiving relaxin alone or in the BEA 1 relaxin restored creatinine clearance to approximately 85% of
group were comparable (Rel 152 6 87 vs. BEA 1 Rel the control level (BEA 0.38 6 0.03 vs. BEA 1 Rel 0.49 6
129 6 69 ng/mL, P 5 NS). Representative time points 0.04 mL/min/100 g body weight, P 5 0.044; Fig. 2). There
of tail-cuff blood pressures are shown in Table 2. ANOVA was also a decrease in albumin excretion in the treated
of the mean arterial pressure (MAP) revealed no signifi- animals (BEA 17.9 6 5.5 vs. BEA 1 Rel 11.9 6 2.8
cant differences within or between any groups over the mg/24 hours), but the difference did not achieve statisti-
time course of the study. cal significance.
As expected, in animals receiving only BEA, the se-
Effect of relaxin treatment on interstitial fibrosisrum creatinine rose to 0.83 6 0.04 mg/dL, a 30% increase
and its mediatorsover control. In the animals receiving relaxin, serum
creatinine levels were indistinguishable from those of The kidneys of rats that received BEA showed com-
the controls (controls 0.58 6 0.04 vs. BEA 1 Rel 0.61 6 plete papillary necrosis by one month. At this time, the
0.03 mg/dL; Fig. 1). In the BEA group, the GFR, as normal parenchyma proximal to the papillary stump was
measured by creatinine clearance, decreased by approxi- replaced by fibrous tissue. In the relaxin-treated BEA
mately 33% as compared with controls (controls 0.58 6 animals, there was some degree of papillary necrosis,
but this was less than that seen in animals receiving only0.06 vs. BEA 0.34 6 0.03 mL/min/100 g body weight,
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Fig. 4. Percentage of the corticomedullary area that showed fibrosis.
*P , 0.002 as compared with BEA alone.
Fig. 3. Representative histology of the corticomedullary area at five
weeks. (A) BEA alone. (B) BEA 1 relaxin. Masson’s trichrome stain,
310 at microscope.
Table 3. Number of ED-1 positive cells in the corticomedullary
junction (C-MJ) and glomeruli after one month of treatment
Treatment N C-MJ cells/mm2 Cells/50 glomeruli
None 5 355 6 80 4 6 1
BEA 6 23366616a 8 6 1
Relaxin 6 7046120a,b 5 6 2
BEA 1 relaxin 12 10436236a,b 8 6 1
aSignificantly different from Control at P # 0.05
bSignificantly different from BEA at P # 0.05
BEA (BEA 100% in all animals versus 3 to 21% in the
relaxin-treated rats).
At the corticomedullary junction in the BEA-treated
rats (Fig. 3A), there was a marked interstitial fibrosis Fig. 5. Immunohistochemical staining for transforming growth fac-
tor-b (TGF-b). (A) BEA alone. There is an increase in the stainingcharacterized by collagen deposition, a mononuclear cell
intensity in the tubules adjacent to the fibrosis. (B) BEA 1 Relaxin.infiltrate, tubular dilation, and tubular atrophy. In the
There is an apparent decrease in staining intensity in the tubules. Fast
cortex, many of the glomeruli showed thickening of Bow- red naphthol antibody visualization counterstained with hematoxylin
(310 at microscope).man’s capsule. In a comparable section of the corti-
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relaxin, the intensity of TGF-b staining was not different
than the controls and was significantly lower than that
of BEA-treated animals.
Relaxin alone did not alter the gelatinase activity lev-
els compared with the controls (cortex 105 6 4 vs. 103 6
4; medulla 102 6 12 vs. 97 6 10 mg gelatin degraded/
h/mg tissue protein, control vs. relaxin, respectively). As
we have previously reported, BEA-induced fibrosis was
accompanied by a significant decrease in gelatinase activ-
ity in both cortex and medulla. There were no changes
in the animals treated with relaxin (cortex 64 6 11 vs.
59 6 4; medulla 58 6 14 vs. 38 6 4 mg gelatin degraded/
h/mg tissue protein, BEA vs. BEA 1 relaxin, respec-Fig. 6. Comparison of TGF-b staining intensities. Control 1.56 6 0.13,
tively).BEA 2.77 6 0.29, BEA 1 relaxin 1.60 6 0.21. BEA 1 relaxin treatment:
BEA one week before, then relaxin treatment for four weeks. *P ,
0.05 compared with BEA alone; #P , 0.05 compared with the control.
DISCUSSION
Relaxin is a heterodimeric hormone of 6000 Daltons
that belongs to the insulin growth factor family. It is
comedullary junction from a relaxin-treated BEA rat, found most abundantly in pregnancy but is also present
the majority of the tubules were preserved, yet there in nonpregnant women and men. Relaxin has a broad
were still some localized areas of increased collagen de- range of biologic activities, including induction of colla-
position and cellular infiltrate (Fig. 3B). Using morpho- gen remodeling in fibrotic tissue, softening of the cervix
metric techniques, we quantitated the percentage of the at parturition, inhibition of uterine contractions, and
area at the corticomedullary junction composed of fi- growth of the mammary gland [9]. In human dermal
brous tissue. In the BEA animals, fibrosis accounted fibroblasts, relaxin modulates collagen deposition by de-
for approximately 20% of the corticomedullary junction creasing collagen synthesis and increasing its degrada-
(19.2 6 3.4%, N 5 11), whereas in the relaxin-treated tion [4]. Unemori et al have studied the effects of relaxin
animals, the fibrotic area comprised only 5% (5.0 6 in human lung fibroblasts in vitro [5]. They found that
1.9%, N 5 11, P , 0.002; Fig. 4). This is the equivalent relaxin inhibited TGF-b–induced procollagen and fi-
of a 75% decrease in the extent of fibrosis. bronectin overexpression in a dose-dependent fashion
There were no significant differences in the number and was associated with increased collagenase activity.
of ED-1–positive cells in the glomeruli of any group. Their study also examined the effect of a continuous
At the corticomedullary junction, BEA caused a sixfold infusion of relaxin on bleomycin-induced pulmonary fi-
increase in macrophage infiltration, indicative of a sus- brosis in mice. The striking increase in the hydroxypro-
tained chronic inflammation. In the relaxin-treated BEA line content of the lung usually seen in that model was
animals, there was a decrease of over 50% in the number dramatically reduced by relaxin, and the histologic de-
of these cells compared with BEA alone (Table 3). gree of pulmonary fibrosis was markedly attenuated. In
There was a uniform basal level of TGF-b staining in clinical trials in patients with scleroderma, relaxin has
the tubules in the control rat. The staining intensity was been found to be safe and well tolerated [10], raising
markedly increased in the tubules in BEA animals. Tu- the possibility that relaxin might be clinically useful in
bules adjacent to areas of fibrosis showed intensified diminishing collagen accumulation and fibrosis in human
but nonuniform staining for TGF-b (Fig. 5A), while the fibrotic diseases.
uninvolved areas of the kidney showed no increase in The BEA model of papillary necrosis is a convenient,
tubular staining. In the animals treated with relaxin, reproducible method to study renal interstitial fibrosis.
there was a decrease in tubular TGF-b staining, in associ- A single dose induces papillary necrosis that is histologi-
ation with an overall decrease in fibrosis (Fig. 5B). The cally evident at seven days. At this time, there is a loss
heterogeneous staining pattern of TGF-b seen in Figure of the epithelium of the papillary tip, dissolution of the
5 would have made total kidney TGF-b levels difficult tubular structures within the papilla, and a mild intersti-
to interpret. For this reason, we measured the TGF-b tial fibrosis. In our current study, relaxin infusion was
staining intensities in the tubules next to the fibrosis and begun one week after the induction of papillary necrosis
compared them with the normal tubules in the same by BEA in order to elucidate whether relaxin would
section. These results are summarized in Figure 6. BEA- be able to inhibit the fibrotic process initiated by this
treated animals had a 77% increase in TGF-b staining compound.
Our results clearly show that in animals in which papil-as compared with the controls. In BEA animals receiving
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lary necrosis had been well established, relaxin adminis- in various diseases [13]. Studies have now shown that
tration prevented the progression of the necrosis and up-regulation of TGF-b is associated with an increase
had a significant impact on preserving renal function, as in matrix accumulation in several fibrotic renal diseases
evidenced by the restoration of creatinine clearance to [14, 15]. In our earlier studies, we demonstrated an in-
85% of control levels. This was comparable to the degree crease in TGF-b expression in the BEA model [1, 2]. In
of improvement we have seen in animals treated with the present study, four weeks of relaxin administration
ACE inhibitors [1]. was accompanied by a decrease to control levels in the
In parallel with relaxin’s ability to preserve renal func- tissue expression of TGF-b, suggesting that relaxin may
tion, it also preserved renal structure. The relaxin- protect against renal scarring. Unemori et al have pre-
treated animals demonstrated a nearly normal renal ar- viously shown in vitro that relaxin inhibits TGF-b’s fi-
chitecture in contrast to the extensive fibrosis and tubular brotic actions in a dose-dependent manner [5]. Our find-
dilation caused by BEA alone. Relaxin administration ing of decreased TGF-b staining intensity in the treated
was associated with a 75% decrease in the deposition of animals extends that observation to an in vivo model.
collagen in the corticomedullary junction. In association One mechanism by which relaxin is thought to prevent
with the decreased fibrosis, tubular structure was also fibrosis is by increasing collagenase activity, as shown in
largely maintained. This is the first study to show a de- experiments using human lung fibroblasts in vitro [9]. In
crease in fibrosis in the kidneys with relaxin treatment. an earlier study, we have shown that BEA administration
Indeed, the improvement in the degree of fibrosis was is associated with an early (first day) decrease in medul-
quite remarkable. One cannot help but hypothesize that lary gelatinase activity, which remained suppressed for
the amelioration of fibrosis by relaxin was key to main- the 30 days of the study [2]. In the present study, we
taining renal function despite the administration of BEA, confirmed that BEA-induced interstitial fibrosis was as-
a potent initiator of renal fibrosis. sociated with a decrease in gelatinase activity, which was
The mechanism whereby relaxin exerted its protective not altered by relaxin. These observations were made at
effect was studied in detail. Blood pressure control plays 30 days and therefore do not preclude an earlier change
an important role in the progression of many renal dis- in gelatinase activity or changes in interstitial collagenase
eases. In our study, relaxin did not alter systemic blood activity that may be important in preventing the onset
pressure in control or experimental animals, suggesting of fibrosis.
that blood pressure was not a significant factor. Given In conclusion, in this model of chronic renal interstitial
that hypertension is not a prominent feature of this fibrosis, relaxin administration resulted in an improve-
model, this was expected. Our findings are in agreement ment in GFR, a decrease in the number of ED-1 positive
with those of Danielson, Sherwood, and Conrad, who cells, a decrease in immunohistochemical staining of
also did not show a change in MAP with short-term TGF-b, and a decrease in the amount of fibrosis in the
relaxin infusion [11]. However, they did show an increase kidney. The ability of relaxin to prevent the progression
in GFR, which they attributed to renal nitric oxide pro- of fibrosis, as measured both functionally and histologi-
duction. We do not believe that the improvement in cally, makes it tempting to suggest that relaxin has prom-
GFR seen in the relaxin-treated BEA animals was simply ise as a therapeutic agent for the treatment of a multitude
a hemodynamic effect, because normal animals infused of renal diseases having interstitial fibrosis as a part of
with relaxin did not show an increase in GFR. Further- their pathologic picture.
more, the improvement in GFR was associated with a
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